The U.S. Food and Drug Administration approved its first COVID-19 treatment: Gilead Science Inc.’s antiviral drug remdesivir. The FDA and Foster City-based Gilead (Nasdaq: GILD) announced the news on Oct. 22.

As an antiviral drug, remdesivir works to stop replication of SARS-CoV-2, the virus that causes COVID-19.

The approval is based on three randomized controlled trials. One notable finding was that the drug shortened time to recovery by five days, from 15 days to 10 days on average.

Previously the FDA authorized the drug for emergency use. The drug was given to President Donald Trump, according to the Associated Press.

Gilead markets remdesivir under the name Veklury. The drug is administered intravenously and may only be used in a hospital setting.